HRP20180411T1 - Predlijekovi inhibitora aminokinazolinske kinaze - Google Patents
Predlijekovi inhibitora aminokinazolinske kinaze Download PDFInfo
- Publication number
- HRP20180411T1 HRP20180411T1 HRP20180411TT HRP20180411T HRP20180411T1 HR P20180411 T1 HRP20180411 T1 HR P20180411T1 HR P20180411T T HRP20180411T T HR P20180411TT HR P20180411 T HRP20180411 T HR P20180411T HR P20180411 T1 HRP20180411 T1 HR P20180411T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- hydrate
- compound
- acceptable salt
- butylsulfonyl
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical compound C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- MJLYDVMFNHZMLV-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-5-ylamino)-6-tert-butylsulfonylquinazolin-7-yl]oxyethyl dihydrogen phosphate Chemical group C1=C2SC=NC2=CC(NC2=C3C=C(C(=CC3=NC=N2)OCCOP(O)(O)=O)S(=O)(=O)C(C)(C)C)=C1 MJLYDVMFNHZMLV-UHFFFAOYSA-N 0.000 claims 2
- 208000009766 Blau syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- -1 calcium (I) 2-((4-(benzo[d]thiazol-5-ylamino)-6-( tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl hydrogen phosphate trihydrate Chemical compound 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- PSQVKVLMMHZRDC-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-5-ylamino)-6-tert-butylsulfonylquinazolin-7-yl]oxyethyl dihydrogen phosphate;hydrate;hydrochloride Chemical compound O.Cl.C1=C2SC=NC2=CC(NC2=C3C=C(C(=CC3=NC=N2)OCCOP(O)(O)=O)S(=O)(=O)C(C)(C)C)=C1 PSQVKVLMMHZRDC-UHFFFAOYSA-N 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 108090000426 Caspase-1 Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Claims (11)
1. Spoj, naznačen time što je 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)kinazolin-7-il)oksi)etil-dihidrogenfosfat, formule:
[image]
ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat.
2. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat, u skladu s patentnim zahtjevom 1, naznačen time što je 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)kinazolin-7-il)oksi)etil-dihidrogenfosfat.
3. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat, u skladu s patentnim zahtjevom 1, naznačen time što je dinatrijev 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)kinazolin-7-il)oksi)etil-fosfat.
4. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat, u skladu s patentnim zahtjevom 1, naznačen time što je kalcijev (I) 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)kinazolin-7-il)oksi)etil-hidrogenfosfat trihidrat.
5. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat, u skladu s patentnim zahtjevom 1, naznačen time što je 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)kinazolin-7-il)oksi)etil-dihidrogenfosfat-hidroklorid monohidrat.
6. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, ili njezin hidrat, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, kao i farmaceutski prihvatljivu pomoćnu tvar.
7. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je namijenjen upotrebi u terapiji.
8. Spoj ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je namijenjen upotrebi u liječenju bolesti ili poremećaja koji se bira između uveitisa, sindroma groznice povezanim s interleukin-1-konvertirajućim enzimom, dermatitisa, akutne ozljede pluća, dijabetesa melitusa tip 2, artritisa, reumatoidnog artritisa, ulceroznog kolitisa, Crohnove bolesti, upalne crijevne bolesti s ranim početkom, ekstraintestinalne upalne crijevne bolesti, sprječavanja ishemijsko-reperfuzijske ozljede u presatku čvrstog organa, nealkoholnog steatohepatitisa, alkoholnog steatohepatitisa, autoimunog hepatitisa, astme, reakcije presatka prema domaćinu, sistemnog eritematoznog lupusa, multiple skleroze, sarkoidoze, Blauovog sindroma/sarkoidoze s ranim početkom, Wegnerove granulomatoze, te intersticijske plućne bolesti.
9. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se bolest ili poremećaj bira između Crohnove bolesti, ulceroznog kolitisa i Blauovog sindroma.
10. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat, u skladu s patentnim zahtjevom 4, naznačen time što je kristalni kalcijev (I) 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)kinazolin-7-il)oksi)etil-hidrogenfosfat trihidrat, koji ima PXRD kao na Slici 1.
11. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njezin hidrat, u skladu s patentnim zahtjevom 5, naznačen time što je kristalni 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)kinazolin-7-il)oksi)etil-dihidrogenfosfat-hidroklorid monohidrat, koji ima PXRD kao na Slici 2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700422P | 2012-09-13 | 2012-09-13 | |
| US201361767387P | 2013-02-21 | 2013-02-21 | |
| PCT/US2013/059619 WO2014043446A1 (en) | 2012-09-13 | 2013-09-13 | Prodrugs of amino quinazoline kinase inhibitor |
| EP13837571.2A EP2895174B1 (en) | 2012-09-13 | 2013-09-13 | Prodrugs of amino quinazoline kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180411T1 true HRP20180411T1 (hr) | 2018-04-20 |
Family
ID=50278703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180411TT HRP20180411T1 (hr) | 2012-09-13 | 2018-03-08 | Predlijekovi inhibitora aminokinazolinske kinaze |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US9586953B2 (hr) |
| EP (2) | EP3323819B1 (hr) |
| JP (1) | JP6246813B2 (hr) |
| KR (1) | KR102101527B1 (hr) |
| CN (1) | CN104619327B (hr) |
| AR (1) | AR092529A1 (hr) |
| AU (1) | AU2013315396B2 (hr) |
| BR (1) | BR112015005694A2 (hr) |
| CA (1) | CA2886467C (hr) |
| CL (1) | CL2015000614A1 (hr) |
| CR (1) | CR20150132A (hr) |
| CY (1) | CY1120236T1 (hr) |
| DK (1) | DK2895174T3 (hr) |
| DO (1) | DOP2015000060A (hr) |
| EA (1) | EA028146B1 (hr) |
| ES (1) | ES2663237T3 (hr) |
| HK (2) | HK1212223A1 (hr) |
| HR (1) | HRP20180411T1 (hr) |
| HU (1) | HUE036347T2 (hr) |
| IL (1) | IL237263B (hr) |
| LT (1) | LT2895174T (hr) |
| ME (1) | ME02985B (hr) |
| MX (1) | MX371356B (hr) |
| NZ (1) | NZ628452A (hr) |
| PE (1) | PE20150635A1 (hr) |
| PH (1) | PH12015500363B1 (hr) |
| PL (1) | PL2895174T3 (hr) |
| PT (1) | PT2895174T (hr) |
| RS (1) | RS57144B1 (hr) |
| SG (1) | SG11201501139RA (hr) |
| SI (1) | SI2895174T1 (hr) |
| TW (1) | TWI592417B (hr) |
| WO (1) | WO2014043446A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| WO2014128622A1 (en) | 2013-02-21 | 2014-08-28 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
| GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| CA3019137A1 (en) | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | Soluble c5ar antagonists |
| UA123287C2 (uk) | 2016-09-15 | 2021-03-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Гетероарилкарбоксамідні сполуки як інгібітори ripk2 |
| CN112638905A (zh) * | 2018-08-28 | 2021-04-09 | 南京明德新药研发有限公司 | 作为rip2激酶抑制剂的喹唑啉类衍生物 |
| WO2020094613A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nod2 inhibitors for the treatment of hereditary periodic fevers |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916135A (en) | 1989-05-08 | 1990-04-10 | Hoechst Roussel Pharmaceuticals Inc. | N-heteroaryl-4-quinolinamines |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
| WO1998005647A1 (en) | 1996-08-01 | 1998-02-12 | Dow Agrosciences Llc | Quinolinium derivatives having fungicidal activity |
| NZ334125A (en) | 1996-09-25 | 2000-10-27 | Zeneca Ltd | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| IL142257A0 (en) | 1998-10-01 | 2002-03-10 | Astrazeneca Ab | Amide derivatives, process for their preparation, compositions containing them and use thereof in the manufacture of a medicament for the treatment of cytokine-mediated diseases |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| RU2002110461A (ru) * | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
| WO2001055116A2 (en) | 2000-01-28 | 2001-08-02 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US7371765B2 (en) | 2000-08-09 | 2008-05-13 | Astrazeneca Ab | Quinoline derivatives having VEGF inhibiting activity |
| US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
| GB0104422D0 (en) | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| AU2002245709A1 (en) | 2001-03-23 | 2002-10-08 | Bayer Corporation | Rho-kinase inhibitors |
| AR035791A1 (es) | 2001-03-23 | 2004-07-14 | Bayer Corp | Compuesto n,n-diheterociclico de amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y proceso para la preparacion del compuesto |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| WO2003026666A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
| HU229477B1 (en) | 2001-12-24 | 2014-01-28 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
| US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| US20040122161A1 (en) | 2002-12-21 | 2004-06-24 | Paul Charles W. | Hot melt adhesive based on acrylic block copolymers |
| NZ540698A (en) | 2002-12-24 | 2008-05-30 | Astrazeneca Ab | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| EP1636195A1 (en) | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
| WO2005003100A2 (en) | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| GB0321620D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| SI1667991T1 (sl) * | 2003-09-16 | 2008-10-31 | Astrazeneca Ab | Kinazolinski derivati kot inhibitorji tirozin kinaze |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| AU2005249503B2 (en) | 2003-11-10 | 2011-08-25 | Vertex Pharmaceuticals Incorporated | ICE inhibitors for the treatment of autoinflammatory diseases |
| BRPI0418102A (pt) | 2003-12-23 | 2007-04-27 | Pfizer | derivados de quinolina |
| US7687502B2 (en) | 2004-03-23 | 2010-03-30 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| US20070299092A1 (en) | 2004-05-20 | 2007-12-27 | Wyeth | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors |
| WO2005120509A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| FR2873695A1 (fr) | 2004-07-30 | 2006-02-03 | Palumed Sa | Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien |
| ATE445617T1 (de) | 2004-12-22 | 2009-10-15 | Bayer Schering Pharma Ag | Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| ITMI20052008A1 (it) | 2005-10-21 | 2007-04-22 | Ctg Pharma S R L | Nuovi antimalarici derivati della 4-aminochinolina |
| FR2902100A1 (fr) | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
| US7511063B2 (en) | 2006-08-16 | 2009-03-31 | Schering Corporation | High affinity quinoline-based kinase ligands |
| JP2008063278A (ja) | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | １−ピリジン−４−イル−インドール類の製造方法 |
| CA2662587C (en) | 2006-09-11 | 2013-08-06 | Curis, Inc. | Quinazoline based egfr inhibitors |
| KR20090077914A (ko) | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | 항증식제로서의 다작용성 소분자 |
| SG174774A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
| TW200829555A (en) | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| WO2008119771A2 (en) | 2007-03-30 | 2008-10-09 | Clanotech Ab | Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors |
| CN101663293B (zh) | 2007-04-23 | 2013-07-31 | 塞诺菲-安万特股份有限公司 | 作为p2y12拮抗剂的喹啉-甲酰胺衍生物 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CA2964162C (en) | 2007-06-01 | 2019-12-31 | Wyeth Llc | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene |
| CN101362719B (zh) | 2007-08-06 | 2012-04-18 | 北京师范大学 | 喹啉类衍生物以及包含其的组合物 |
| US7939546B2 (en) | 2007-10-12 | 2011-05-10 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
| US7790746B2 (en) | 2007-10-12 | 2010-09-07 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
| EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
| GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| US20090226443A1 (en) | 2008-03-06 | 2009-09-10 | Genentech, Inc. | Combination therapy with c-met and egfr antagonists |
| CA2739302A1 (en) | 2008-10-17 | 2010-04-22 | Brendan C. Bender | Treatment method |
| DE102008062566A1 (de) * | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
| PH12012500097A1 (en) | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
| US20130005726A1 (en) * | 2010-03-08 | 2013-01-03 | Derek Abbott | Compositions and methods for treating inflammatory disorders |
| EP2552211A4 (en) | 2010-03-26 | 2013-10-23 | Glaxo Group Ltd | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER |
| WO2011120026A1 (en) | 2010-03-26 | 2011-09-29 | Glaxo Group Limited | Pyrazolyl-pyrimidines as kinase inhibitors |
| EP2552208A4 (en) | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS |
| ES2552977T3 (es) * | 2010-05-07 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolinas como inhibidores de quinasa |
| UY33549A (es) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| RU2568258C2 (ru) | 2011-02-28 | 2015-11-20 | Саншайн Лейк Фарма Ко., Лтд | Замещенные соединения хинолина и способы их использования |
| CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| WO2014128622A1 (en) | 2013-02-21 | 2014-08-28 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
-
2013
- 2013-09-11 TW TW102132715A patent/TWI592417B/zh not_active IP Right Cessation
- 2013-09-11 AR ARP130103247A patent/AR092529A1/es unknown
- 2013-09-13 CA CA2886467A patent/CA2886467C/en not_active Expired - Fee Related
- 2013-09-13 PT PT138375712T patent/PT2895174T/pt unknown
- 2013-09-13 PL PL13837571T patent/PL2895174T3/pl unknown
- 2013-09-13 SI SI201330964T patent/SI2895174T1/en unknown
- 2013-09-13 HU HUE13837571A patent/HUE036347T2/hu unknown
- 2013-09-13 DK DK13837571.2T patent/DK2895174T3/en active
- 2013-09-13 ME MEP-2018-80A patent/ME02985B/me unknown
- 2013-09-13 BR BR112015005694A patent/BR112015005694A2/pt active Search and Examination
- 2013-09-13 CN CN201380047261.2A patent/CN104619327B/zh not_active Expired - Fee Related
- 2013-09-13 LT LTEP13837571.2T patent/LT2895174T/lt unknown
- 2013-09-13 NZ NZ628452A patent/NZ628452A/en not_active IP Right Cessation
- 2013-09-13 SG SG11201501139RA patent/SG11201501139RA/en unknown
- 2013-09-13 EA EA201590561A patent/EA028146B1/ru not_active IP Right Cessation
- 2013-09-13 PE PE2015000277A patent/PE20150635A1/es active IP Right Grant
- 2013-09-13 US US14/397,218 patent/US9586953B2/en active Active
- 2013-09-13 JP JP2015532068A patent/JP6246813B2/ja not_active Expired - Fee Related
- 2013-09-13 WO PCT/US2013/059619 patent/WO2014043446A1/en active Application Filing
- 2013-09-13 EP EP17209342.9A patent/EP3323819B1/en active Active
- 2013-09-13 EP EP13837571.2A patent/EP2895174B1/en active Active
- 2013-09-13 ES ES13837571.2T patent/ES2663237T3/es active Active
- 2013-09-13 AU AU2013315396A patent/AU2013315396B2/en not_active Ceased
- 2013-09-13 RS RS20180281A patent/RS57144B1/sr unknown
- 2013-09-13 KR KR1020157006176A patent/KR102101527B1/ko active IP Right Grant
- 2013-09-13 MX MX2015003276A patent/MX371356B/es active IP Right Grant
-
2015
- 2015-02-16 IL IL237263A patent/IL237263B/en active IP Right Grant
- 2015-02-18 PH PH12015500363A patent/PH12015500363B1/en unknown
- 2015-03-12 CL CL2015000614A patent/CL2015000614A1/es unknown
- 2015-03-13 CR CR20150132A patent/CR20150132A/es unknown
- 2015-03-13 DO DO2015000060A patent/DOP2015000060A/es unknown
-
2016
- 2016-01-08 HK HK16100176.8A patent/HK1212223A1/xx not_active IP Right Cessation
- 2016-03-25 US US15/080,969 patent/US9695161B2/en active Active
-
2017
- 2017-05-30 US US15/608,099 patent/US20170258794A1/en not_active Abandoned
-
2018
- 2018-03-08 HR HRP20180411TT patent/HRP20180411T1/hr unknown
- 2018-03-09 CY CY20181100287T patent/CY1120236T1/el unknown
- 2018-08-15 HK HK18110508.4A patent/HK1251222A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180411T1 (hr) | Predlijekovi inhibitora aminokinazolinske kinaze | |
| JP2015529681A5 (hr) | ||
| HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
| HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| NZ629442A (en) | Heterocyclyl compounds as mek inhibitors | |
| PH12014502886B1 (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| WO2013066838A1 (en) | Compounds and methods | |
| HRP20171150T1 (hr) | Novi spojevi | |
| JP2015520158A5 (hr) | ||
| JP2016509051A5 (hr) | ||
| MX2009011812A (es) | Aminopirimidinas utiles como inhibidores de cinasa. | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| IN2014MN01919A (hr) | ||
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| IN2014MN02104A (hr) | ||
| JP2016503785A5 (hr) | ||
| MX2011010732A (es) | Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer. | |
| PH12016500394A1 (en) | Polymorphic form of pyrrole derivative and intermediate thereof | |
| IN2012DN02502A (hr) | ||
| JP2014521748A5 (hr) | ||
| HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
| JP2014509637A5 (hr) |